BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 14625173)

  • 1. [Clinical study of tacrolimus in postoperative treatment of patients with renal transplantation for diabetic end-stage renal disease].
    Yu LX; Shan HT; Fu SJ; Du CF; Ma JJ; Xu J; Deng WF; Wang YB
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1146-8. PubMed ID: 14625173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
    Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M
    J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial.
    McDiarmid SV; Busuttil RW; Ascher NL; Burdick J; D'Alessandro AM; Esquivel C; Kalayoglu M; Klein AS; Marsh JW; Miller CM
    Transplantation; 1995 Feb; 59(4):530-6. PubMed ID: 7533345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
    Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rejection after simultaneous pancreas-kidney transplantation.
    Arbogast H; Malaise J; Illner WD; Tarabichi A; Dieterle C; Landgraf R; Land W;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii11-7, ii62. PubMed ID: 15814544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
    Steurer W; Malaise J; Mark W; Koenigsrainer A; Margreiter R;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii54-62. PubMed ID: 15814551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation.
    Platz KP; Mueller AR; Jonas S; Blumhardt G; Bechstein WO; Lobeck H; Neuhaus HL
    Clin Transplant; 1995 Jun; 9(3 Pt 1):146-54. PubMed ID: 7549052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506.
    Platz KP; Mueller AR; Blumhardt G; Bachmann S; Bechstein WO; Kahl A; Neuhaus P
    Transplantation; 1994 Jul; 58(2):170-8. PubMed ID: 7518975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial.
    Saudek F; Malaise J; Boucek P; Adamec M;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii3-10, ii62. PubMed ID: 15814547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group.
    Reichart B; Meiser B; Viganò M; Rinaldi M; Martinelli L; Yacoub M; Banner NR; Gandjbakhch I; Dorent R; Hetzer R; Hummel M
    J Heart Lung Transplant; 1998 Aug; 17(8):775-81. PubMed ID: 9730426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
    Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results.
    Krämer BK; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Ortuño J; Sester U; Kunzendorf U; Dietl KH; Bonomini V; Rigotti P; Ronco C; Tabernero JM; Rivero M; Banas B; Mühlbacher F; Arias M; Montagnino G;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2386-92. PubMed ID: 18258740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
    Greig P; Lilly L; Scudamore C; Erb S; Yoshida E; Kneteman N; Bain V; Ghent C; Marotta P; Grant D; Wall W; Tchervenkov J; Barkun J; Roy A; Marleau D; McAlister V; Peltekian K
    Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.
    Tang SC; Chan KW; Tang CS; Lam MF; Leung CY; Tse KC; Li CS; Ho YW; Tong MK; Lai KN; Chan TM;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3243-51. PubMed ID: 16877482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506?
    Mueller AR; Platz KP; Blumhardt G; Bechstein WO; Steinmüller T; Christe W; Hopf U; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Jun; 9(3 Pt 1):176-84. PubMed ID: 7549057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.